Pattern Computer®, Inc. (“Pattern” or “the Company”) today
announced the availability of the first paper produced by a
research collaboration with Lawrence Berkeley National Laboratory
(LBNL) and Los Alamos National Laboratory (LANL) and funded by the
U.S. Department of Energy and the Defense Threat Reduction Agency
(DTRA), which addresses the clear and critical need for pathogen
agnostic diagnostics that can be quickly and effectively performed
at point of need. Leveraging the Company’s AI-enabled Pattern
Discovery Engine™ (PDE) along with its ProSpectral™ multi-disease
diagnostics research platform, the resulting manuscript
“Reagent-free Hyperspectral Diagnosis of SARS-CoV-2 Infection in
Saliva Samples” is available on an online preprint server at
medRxiv at
www.medrxiv.org/content/10.1101/2024.06.03.24308300v2.full-text and
is being submitted to scientific journals for consideration for
publication.
From the Manuscript: Reagent-free
Hyperspectral Diagnosis of SARS-CoV-2 Infection in Saliva
Samples
To our knowledge, this establishes
the fastest hyperspectral diagnostic platform (3
seconds/measurement), with no preprocessing and in a small form
factor, and executable with liquid (clinical) samples, without
ligands or reagents. Our data demonstrates that the sensitivity of
this assay is comparable to gold-standard PCR-based assays; and
that the signatures are specific to COVID-19 and not associated
with influenza and other respiratory pathogens – establishing the
truly agnostic nature of the platform.
Preparedness against unanticipated
pathogens and democratization of diagnostics requires moving away
from technologies that demand specific reagents; and relying on
intrinsic biochemical properties that can, theoretically, inform on
all pathologies. Integration of hyperspectral sensors and in-line
machine learning analytics, as reported here, shows the feasibility
of such diagnostics. If realized to full potential, the
ProSpectral™ V1 platform can enable agnostic diagnostics, thereby
improving situational awareness and decision-making at the point of
need; especially in resource-limited settings – enabling the
distribution of newly developed tests for emerging pathogens with
only a software update.
Matt Keener, Pattern Chief Technology Officer, noted, “Employing
Pattern’s ProSpectral platform, an integrated, bench-top
hyperspectral instrument (400-1700 nm) engineered for use with
clinical samples, this study has definitively shown hyperspectral
sensing to enable pathogen agnostic, reagent-free diagnostics.
Pattern invented the first PDE for identifying novel patterns in
complex data that cannot be discovered using conventional
analytical techniques, algorithms, or tools. The Company created
the ProSpectral platform – a portable system capable of continuous
collection of spectral signatures in clinical samples such as
saliva – and combined it with the PDE to generate predictive models
of disease with unmatched accuracy and speed. The instrument may
incorporate pattern recognition via embedded AI/ML algorithms and
can decode the same within seconds at the point of need, without
the need for any reagents. ProSpectral was used in the research
study to capture SARS-CoV-2 infection-related spectral signatures
in saliva. The signatures were analyzed by researchers using tools
including the PDE, which provided explainable predictive metrics
for SARS-CoV-2 infection diagnosis. The methods described are
broadly applicable to diseases and disease states, and the ability
to train and release new explainable models is getting faster with
each generation.”
Mark Anderson, Chair and CEO of Pattern, commented, “Emerging
infectious diseases are a major concern in national health
security. The results from the study highlight the significant
potential of Pattern’s AI-enabled PDE and our ProSpectral platform,
and represent an important step forward in our development efforts
surrounding multi-disease diagnostics research. Pattern is honored
to be a part of this innovative and far-reaching research intended
to enable front-line workers to distinguish between viral,
bacterial, fungal, or parasitic infections in seconds in the
field.”
Mr. Anderson concluded, “We are excited by the findings of this
study, which indicate that ProSpectral is indeed a disruptive new
technology in realizing rapid, reagent-free, pathogen agnostic
diagnostics at the point of need; a critical development that can
truly impact point of care in both clinical diagnostic decision
making, and clinical/military pandemic/outbreak control.”
About ProSpectral™Pattern has
created a line of light-based devices which can detect the presence
of diseases in three seconds. Using 100ul (two drops) of saliva
placed into a small disposable sample container, a broad-spectrum
light source is passed through the saliva and the light absorption
pattern is captured by the device. The device, utilizing an
accurate model of Covid-19’s absorption pattern, identifies an
active Covid-19 infection with 98.8% balanced accuracy in the proof
of concept. In critical environments where no individual shall pass
with Covid-19, the accuracy of the device can be adjusted to 100%
detection with up to 8% false positives. No reagents are required.
The accuracy of each test is nearly equivalent to the current gold
standard of a nasopharyngeal sample processed through an RT-PCR
device. ProSpectral is ideally suited for situations where many
people need to be tested in a short amount of time and/or on a
frequent basis. The non-invasive sample collection eliminates
patient discomfort, simplifies the testing process, and will likely
increase voluntary compliance with regards to testing. The device
is designed to meet FDA 21 CFR 820 and internationally ISO
13485.2016 guidelines. Regulatory approvals will be sought before
availability in each market.
About medRxivmedRxiv
(pronounced "med-archive") is a free online archive and
distribution server for complete but unpublished manuscripts
(preprints) in the medical, clinical, and related health sciences.
Preprints are preliminary reports of work that have not been
certified by peer review. They should not be relied on to guide
clinical practice or health-related behavior and should not be
reported in news media as established information.
medRxiv is for the distribution of preprints - complete but
unpublished manuscripts - that describe human health research
conducted, analyzed, and interpreted according to scientific
principles. Research articles, systematic reviews and
meta-analyses, clinical research design protocols and data articles
may be posted. MedRxiv is not intended for case reports (single or
in series), narrative reviews, editorials, letters, opinion pieces
and hypotheses that lack data, work not premised on modern
biology/physiology or allopathic medicine, laboratory
protocols/recipes, theses, term papers, textbook excerpts or
individual components of research articles such as figures, tables,
and datasets. https://www.medrxiv.org/content/about-medrxiv
About PatternPattern Computer, Inc. uses its
Pattern Discovery Engine™ to solve the most important and
intractable problems in business and medicine. These proprietary
mathematical techniques in advanced AI can find complex patterns in
very-high-order data that have eluded detection by much larger
systems. As the Company applies its computational platform to the
challenging fields of drug discovery and diagnostics, it is also
making major Pattern Discoveries for partners in other sectors,
including extended biotech, materials science, aerospace
manufacturing quality control, veterinary medicine, air traffic
operations, and energy services. See www.patterncomputer.com.
CONTACT: Laura Guerrant-Oiye (808)
960-2642 – laura@patterncomputer.com
The foregoing contains statements about Pattern Computer’s
future that are not statements of historical fact. These statements
are “forward looking statements” for purposes of applicable
securities laws and are based on current information and/or
management’s good faith belief as to future events. The words
“believe,” “expect,” “anticipate,” “project,” “should,” “could,”
“will,” and similar expressions signify forward-looking statements.
Forward-looking statements should not be read as a guarantee of
future performance. By their nature, forward-looking statements
involve inherent risk and uncertainties, which change over time,
and actual performance could differ materially from that
anticipated by any forward-looking statements. Pattern Computer
undertakes no obligation to update or revise any forward-looking
statement.
Copyright © 2024 Pattern Computer Inc. All Rights Reserved.
Pattern Computer, Inc., Pattern Discovery Engine, PatternBio,
TrueXAI, and ProSpectral are trademarks of Pattern Computer Inc. or
its subsidiaries. Other trademarks may be trademarks of their
respective owners.